Avacta Group Plc · LSE:AVCT
Avacta — FY2011 Earnings Presentation
20 slides from Avacta's earnings presentation, Oct 25, 2011
Slide 1: Preliminary Results for the Year Ending 31 July 2011
Avacta Group plc! Innovative analysis and diagnostics ! ! ! ! ! ! ! Preliminary Results for the Year Ending 31 July 2011! October 25th 2011!
Slide 2: Important Notice
Important Notice! This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the “Company”) nor a representation that any dealing in those shares is appropriate. The Company accepts no duty of care whatsoever to the reader of this presentation in respect of its
Slide 3: The Opportunity
The Opportunity! Addressing causes of the spiraling cost of heatlhcare! BIOPHARMACEUTICALS! HEALTH! Complex biological drugs! OPPORTUNITIES to Slow/inadequate diagnosis! provide improved OPPORTUNITIES! analytical and diagnostic >70% failure rate! Longer/wrong treatment! solutions! High cost of drugs
Slide 4: Avacta Group plc
Avacta Group plc! AIM : AVCT (Healthcare Equipment and Services)! Proprietary analytical and diagnostic technology, consumables and reagents for the drug development and healthcare sectors ! ANALYTICAL ANIMAL HEALTH Optim 1000®! AX-1! 4!
Slide 5: Our Markets
Our Markets! Large, rapidly growing healthcare sectors : drug development and diagnostics! Biopharmaceuticals! Point of Care! $202bn by 2013; 20 cagr! Diagnostics! >1/3rd of all drugs in $19bn 2011! development! ! Biotech! Vet Diagnostics! Instrumentation! $3bn! $37bn 5% cagr! No regulatory hurdles!
Slide 6: Avacta Solutions: Optim 1000 Protein Analysis System
Avacta Solutions! Faster, better, cheaper analysis and diagnostics ! Optim® 1000 Protein Analysis System! Optim 1000 is the only product that allows detailed analysis of drugs very early in development to weed out failures early! ! •! Laser scattering and fluorescence! •! 100x less sample required!
Slide 7: Avacta Solutions: AX-1 Rapid Blood Immunoassay System
Avacta Solutions! Healthcare technology with recurring consumables revenues! AX-1 Rapid Blood Immunoassay System! AX-1 allows laboratory standard blood tests, not cut down versions, to be simply carried out in-clinic! •! Rapid, easy to use and very sensitive! •! Multiple analytes in one instrument!
Slide 8: Management Team
Management Team! Extensive commercial experience and world class technical expertise! Group Chief Executive Chief Finance Officer! Chief Executive! Chief Executive ! and Founder ! ! Avacta Analytical ! Avacta Animal Health! Dr Alastair Smith ! Tim Sykes! Chris Dryden! Ged Holmes! ! ! ! ! World class
Slide 9: Avacta Analytical
Avacta Analytical! Solid growth in Optim sales and pipeline ! •! 14 Optim units despatched; revenues up by 150% to £1.24m (2010: £0.50m) ! •! Revenues from Optim and its consumable cartridge increased fifteen fold to £0.81m (2010: £0.05m)! •! Commercial partnership with Pall Corporation extended to
Slide 10: Update on Optim Sales
Update on Optim Sales! Optim in major markets represented by high quality partners ! Cold Spring Biotech! Sales and support in China, Hong Kong and 40+ prospects Taiwan! in USA! 40+ prospects in ! Europe! 30+ prospects in 12! 5! 2! Asia! 2! Pall Life Sciences! Sales and support in USA and Canada! 2!
Slide 11: Avacta Animal Health
Avacta Animal Health! Progressing commercial roll out of AX-1! •! A total of 18 AX-1 tests identified and commercially validated for future development for companion animal and equine markets! •! Multiple tests to be completed during FY 2012! •! AX-1 device to be showcased at London Vet Show during
Slide 12: Financial Information
Avacta Group plc! Financial Information! ! ! ! ! ! ! ! October 25th 2011!
Slide 13: Preliminary Results for the Period Ended 31st July 2011
Preliminary Results for the Period Ended 31st July 2011! Solid growth in underlying revenues and significant reduction in operating losses! ! =* !"#$%&'(")*+$,$"-$.*/012* <* ;* :* >* /:2* /;2* 3456*/+$78%9$#2*/0 12* /<2* (E) Analysts consensus! 13!
Slide 14: Balance Sheet and Cash Flow at 31st July 2011
Balance Sheet and Cash Flow at 31st July 2011! Improving balance sheet and cash flow position! 2009! 2010! 2011! £000! £000! £000! Intangible assets! 7,378! 8,551! 9,298! Tangible assets! 799! 1,238! 1,263! Cash! 878! 1,433! 1,774! Tangible liabilities! (758)! (1,252)! (899)! Net assets! 8,297! 9,97
Slide 15: A Solid Base for Growth
A Solid Base for Growth! A high growth technology and consumables business at an inflexion point! •! Product development completed! Consumables! •! Optim revenues growing strongly! •! AX-1 roll out beginning shortly! Reagents! •! Margin improvements to come! •! Experienced management team! •! Top ti
Slide 16: Appendices
Avacta Group plc! Innovative analysis and diagnostics ! ! ! ! ! ! ! ! Appendices!
Slide 17: Optim 1000 Protein Analysis System
1. Optim 1000 Protein Analysis System ! Faster, better and cheaper analysis reducing drug development risk! Step 1: Load up to 48 Cooled CCD samples into sample Detector holders and place in Laser 2 Laser 3 Laser 1 Optim! Imaging Spectrograph Collection Optics Samples in Multi-Cuvette Plate Heating/
Slide 18: Optim Competitor Analysis
1. Optim Competitor Analysis! Faster, better and cheaper protein analysis reducing drug development risk! •! There is no other single product that delivers the full Optim specification of two simultaneous tests (Tm and Tagg) with high throughput and low volume samples! •! Consider a formulation expe
Slide 19: Optim and Pall Corporation
1. Optim and Pall Corporation! Major commercial partnership with global giant ! •! 3 year distribution agreement for Optim in North America, anticipated to extend to 5 years and to extend to other territories; now extended to SE Asia.! •! Joint analytical services delivery in North America form FY20
Slide 20: AX-1 Technical Details
2. AX-1 Technical Details! Blood testing for a wide range of diseases at the point of care! Disposable test cartridge! Internal view! Blood sample put into cartridge! Two step reaction using preloaded chemicals to 2! generate light signal! Reagents capture 1! 3! AX-1 detects light protein disease si